Navigation Links
First patients at Vanderbilt University Medical Center implanted in EndoStim's LESS GERD clinical trial for gastroesophageal reflux disease (GERD)
Date:4/19/2017

NASHVILLE, Tenn. and DALLAS, April 19, 2017 /PRNewswire/ -- Vanderbilt University Medical Center (VUMC) and EndoStim, Inc., announced that the first patients in Nashville, Tennesse have been implanted with the EndoStim device in the Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. The EndoStim system is a minimally-invasive implantable device designed to provide long-term reflux control by restoring normal function to the esophagus through neurostimulation.

GERD affects nearly 65 million people in the United States1. It occurs when stomach acid or other stomach contents flow back into esophagus, often caused by a weak valve, or sphincter, between the esophagus and the stomach called the lower esophageal sphincter (LES). Frequent and troublesome symptoms can include heartburn, regurgitation, sleep disruption, vocal impairment and respiratory complications. Most GERD is successfully treated with acid blocking medications such as proton pump inhibitors (PPI). However, nearly 30 percent of patients on PPI medication continue to suffer from symptoms. The traditional anti-reflux surgery is laparoscopic fundoplication surgery, a procedure in which the surgeon wraps the top of the stomach around the lower esophagus to reinforce the lower esophageal sphincter. While typically effective, fundoplication can cause significant side effects.

EndoStim(R)LES Stimulation Therapy. (PRNewsFoto/EndoStim)
EndoStim(R)LES Stimulation Therapy. (PRNewsFoto/EndoStim)
EndoStim LES Stimulation Therapy for GERD
EndoStim LES Stimulation Therapy for GERD
EndoStim(R)LES Stimulation Therapy. (PRNewsFoto/EndoStim) EndoStim LES Stimulation Therapy for GERD

The LESS GERD trial will evaluate the safety and efficacy of the EndoStim Lower Esophageal Sphincter (LES) Stimulation System in patients with gastroesophageal reflux disease (GERD) who experience symptoms despite taking high-dose proton pump inhibitor (PPI) medications.

"GERD disrupts the lives of millions of Americans, and many continue to suffer from symptoms like heartburn and regurgitation even when taking PPI medications," commented Dr. Vaezi, M.D. Ph.D., Professor of Medicine at VUMC  and a principal investigator in the study.

"We are excited to start the LESS GERD Clinical trial at Vanderbilt University Medical Center to generate evidence for a novel new treatment for Chronic GERD, an undertreated disease that is disrupting the lives of millions of patients worldwide," said Rohan Hoare, Ph.D., President and Chief Executive Officer of EndoStim. "Unlike many common treatment options that work to alleviate GERD symptoms, EndoStim targets the underlying pathophysiology of GERD with the potential to restore normal function to the lower esophageal sphincter (LES)."

About the Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) Trial
The LESS GERD trial will examine the effects of the EndoStim LES Stimulation System on GERD outcomes such as: esophageal acid exposure; GERD symptoms (heartburn and regurgitation); ability to avoid dependence on PPI medications; and the effect on overall quality of life. A minimum of 110 subjects will be implanted with the EndoStim device. The study is open to GERD patients who are between the ages of 22 and 75; have been diagnosed with GERD; have taken daily PPI medication and whose GERD symptoms are not completely resolved or have side effects from the PPI; and have had no prior surgery involving the esophagus.

Patients seeking information on the trial should visit: www.lessgerd.com.

About EndoStim
EndoStim is a medical device company based in Dallas, Texas, and Nijmegen, The Netherlands, developing and commercializing a revolutionary treatment for GERD. The EndoStim LES Stimulation System is CE Marked for patients with gastroesophageal reflux disease with symptom duration of six months or longer, and is available in a number of countries throughout Europe, Latin America, and Asia Pacific. The EndoStim system is not approved for sale in the US and is limited by US federal law to investigational use only. For more information, visit www.endostim.com.

1 National Institute of Diabetes and Digestive and Kidney Diseases, Definition and Facts for GER and GERD, http://www.niddk.nih.gov/health-information/health-topics/digestive-diseases/ger-and-gerd-in-adults/Pages/definition-facts.aspx. Accessed June 9, 2016.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/first-patients-at-vanderbilt-university-medical-center-implanted-in-endostims-less-gerd-clinical-trial-for-gastroesophageal-reflux-disease-gerd-300442400.html


'/>"/>
SOURCE EndoStim
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia
2. Atara Biotherapeutics, Inc. Leases First of Nine Buildings Underway in Conejo Spectrum by SRG Commercial
3. Cogentix Medical to Report First Quarter Results on May 2, 2017
4. Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America
5. Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2017
6. Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017
7. MiMedx Announces First Quarter 2017 Revenue to Exceed High End of Guidance
8. FDA approves first drug to treat tardive dyskinesia
9. The Mobility Zone, Presented By Stryker, Set To Make Its First Ever Appearance At RBC Heritage
10. CSA Medical announces first publication of the RejuvenAir Metered Cryospray System in the American Journal of Respiratory and Critical Care Medicine
11. Lilly Confirms Date and Conference Call for First-Quarter 2017 Financial Results Announcement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2018)... ... 16, 2018 , ... AMGtime will be exhibiting at the ... At booth 1940, AMGtime will showcase time, labor management, and scheduling solutions including ... specialized Skilled Nursing Facility module . , Designed to appease common pain ...
(Date:10/13/2018)... ... October 12, 2018 , ... David Young ... which was used in the Lockheed F22 Aircraft. Today, he announces the invention ... AF-Arrhythmia, which can lead to sudden cardiac death (SCD). , The Two-Dimensional Arrhythmia ...
(Date:10/11/2018)... ... October 11, 2018 , ... ... today that it has completed the strategic combination of RevSpring and Apex ... revenue cycle engagement, billing, and payments solutions generating over one billion consumer ...
Breaking Medicine Technology:
(Date:10/13/2018)... ... 12, 2018 , ... At HEI Health, we believe tomorrow’s healthcare can be ... year’s National Healthcare CXO Fall Summit by Marcus Evans. HEI will be hosting an ... Experience challenges with leading healthcare providers. , Marcus Evans National Healthcare CXO Summit ...
(Date:10/13/2018)... Mo. (PRWEB) , ... October 12, 2018 , ... Convoy ... hardest-hit communities. Convoy of Hope has a distribution site set up to serve hurricane ... , , Up to 50 additional truckloads of supplies are ...
(Date:10/13/2018)... , ... October 13, 2018 , ... ... on Sports, Fitness & Nutrition, has announced LaRhonda Burley as its new Vice ... congressionally chartered in 2010 to support and strengthen the mission of the President's ...
(Date:10/11/2018)... (PRWEB) , ... October 11, 2018 , ... ... for 2018. The medalists are leading scientists in their fields recognized by DuPont ... advancing science and technology relevant to the future of food, nutrition and health. ...
(Date:10/11/2018)... ... October 11, 2018 , ... ... quite vulnerable to manipulation,” warns former U.S. Department of Homeland Security deputy assistant ... Vulnerable and How We Can Stop it. , Pointing to the ability of ...
Breaking Medicine News(10 mins):